12/17
06:14 am
regn
Rating for REGN
Low
Report
Rating for REGN
11/16
06:05 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/16
06:05 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/15
08:04 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
11/15
08:04 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
11/15
06:03 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
11/15
05:56 am
regn
Rating for REGN
Medium
Report
Rating for REGN
11/15
05:56 am
regn
Rating for REGN
Medium
Report
Rating for REGN
11/14
04:16 pm
regn
Regeneron initiated with bullish view at Wolfe Research
Medium
Report
Regeneron initiated with bullish view at Wolfe Research
11/14
04:16 pm
regn
Regeneron initiated with bullish view at Wolfe Research
Medium
Report
Regeneron initiated with bullish view at Wolfe Research
11/14
08:09 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.
11/14
07:55 am
regn
Rating for REGN
Low
Report
Rating for REGN
11/14
07:55 am
regn
Rating for REGN
Low
Report
Rating for REGN
11/6
08:53 am
regn
Rating for REGN
Medium
Report
Rating for REGN
11/6
08:53 am
regn
Rating for REGN
Medium
Report
Rating for REGN
11/1
01:57 pm
regn
Rating for REGN
Low
Report
Rating for REGN
11/1
01:57 pm
regn
Rating for REGN
Low
Report
Rating for REGN
11/1
01:49 pm
regn
Rating for REGN
Low
Report
Rating for REGN
11/1
01:49 pm
regn
Rating for REGN
Low
Report
Rating for REGN
11/1
01:32 pm
regn
Rating for REGN
Low
Report
Rating for REGN
11/1
01:32 pm
regn
Rating for REGN
Low
Report
Rating for REGN
11/1
12:12 pm
regn
Rating for REGN
Low
Report
Rating for REGN
11/1
12:12 pm
regn
Rating for REGN
Low
Report
Rating for REGN
10/25
01:45 pm
regn
Rating for REGN
Low
Report
Rating for REGN
10/25
01:45 pm
regn
Rating for REGN
Low
Report
Rating for REGN